Antimicrob Agents Chemother. 2018 Oct 1. pii: AAC.01686-18. doi: 10.1128/AAC.01686-18. [Epub ahead of print]
Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus.
Cressey TR1,2,3, Harrison L4, Achalapong J5, Kanjanavikai P6, Patamasingh Na Ayudhaya O7, Liampongsabuddhi P8, Siriwachirachai T9, Putiyanun C10, Suriyachai P11, Tierney C4, Salvadori N12, Chinwong D13, Decker L14, Tawon Y12, Murphy TV15, Ngo-Giang-Huong N12,2,14, Siberry GK16, Jourdain G12,2,13; iTAP study team.
Author information
1
PHPT/IRD, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand [email protected].
2
Department of Immunology & Infectious Diseases, Boston, Harvard T.H Chan School of Public Health, MA, USA.
3
Department of Molecular & Clinical Pharmacology, University of Liverpool, UK.
4
Center for Biostatistics in AIDS Research (CBAR), Harvard T.H. Chan School of Public Health, USA.
5
Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
6
Banglamung Hospital, Chonburi, Thailand.
7
Nopparat Rajathanee Hospital, Bangkok, Thailand.
8
Lampang Hospital, Lampang, Thailand.
9
Khon Kaen Hospital, Khon Kaen, Thailand.
10
Chiang Kham Hospital, Phayao, Thailand.
11
Phayao Provincial Hospital, Phayao, Thailand.
12
PHPT/IRD, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
13
Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Thailand.
14
Institut de Recherche pour le Développement (IRD), Unité Mixte Internationale 174-PHPT, Chiang Mai, Thailand.
15
Centers for Disease Control and Prevention, Atlanta, USA.
16
Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Abstract
We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected, HIV-uninfected, women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized-controlled trial were included. Individual plasma tenofovir exposures (AUC0-24) were estimated using a population pharmacokinetic approach. Estimated geometric mean tenofovir AUC0-24 was 20% (95% CI: 19-21%) lower during pregnancy compared to postpartum; this modest reduction in the absence of HBV transmission suggests no dose adjustment is needed.